Table 2.
Comparison of pulmonary function test results, saturation levels, and heart rate in postacute COVID‐19 patients at 4 and 12 weeks
| Group 1 (n = 83) | Group 1 (n = 83) | Group 2 (n = 34) | Group 2 (n = 34) | Group 3 (n = 34) | Group 3 (n = 34) | |||
|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |||
| Week 4 | Week 12 | Week 4 | Week 12 | Week 4 | Week 12 | p* | p** | |
| FVC% | 111 ± 22.8 | 114.3 ± 17.4 | 109.1 ± 15.5 | 111.9 ± 15.2 | 91.3 ± 21.4 a,b* | 97.4 ± 22.7 a,b** | <0.001 | 0.002 |
| FEV1% | 106.5 ± 21.1 | 108.1 ± 20.3 | 104.3 ± 23.3 | 104.5 ± 16.1 | 91.6 ± 19.1 a,b* | 96 ± 21.2 a** | 0.004 | 0.03 |
| FEF25‐75% | 81.47 ± 29.3 | 84.1 ± 27.9 | 88.3 ± 37.2 | 89.2 ± 30.9 | 81 ± 23.5 | 86.1 ± 24.9 | 0.73 | 0.35 |
| DLCO/VA% | 115.1 ± 23.8 | 120.2 ± 18.8 | 111.7 ± 18.1 | 112.8 ± 16.5 | 89.2 ± 21.1 a,b* | 103.9 ± 13.6 a** | <0.001 | <0.001 |
| SO2 (%) | 93.1 ± 4.5 | 94 ± 2.7 | 92.3 ± 3.8 | 93.1 ± 1.3 | 87.1 ± 6.4 a,b* | 91.3 ± 4.7 a** | <0.001 | 0.02 |
| Heart rate (beats/min) | 90.6 ± 11.5 | 88.9 ± 12.5 | 98.5 ± 10.5 | 90.1 ± 8.6 | 104.2 ± 11.3a* | 104.1 ± 11.5a,b** | <0.001 | <0.001 |
Note: Wilcoxon test was used for within‐group comparisons of laboratory parameters and Weeks 4 and 12 (bold indicate statistically significant); Kruskal–Wallis test was used for between‐group comparisons of Week 4 and Week 12 data (p*: comparison of Week 4 data, p**: comparison of Week 12 data, p a: comparison with group 1, p b: comparison between groups 2 and 3).
Abbreviations: %, percent predicted; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; DLCO/VA, diffusing capacity divided by the alveolar volume.